Sarah Sunshine, MD

This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies for sustained therapy in breast and lung cancer.

Hope Rugo, MD; Liz Castronovo, NP; and Stephanie McDonald, NP, discuss practical approaches to thrombocytopenia management during antibody-drug conjugate (ADC) therapy, emphasizing that platelet thresholds should be individualized rather than applied as rigid cutoffs.

Hope Rugo, MD; Aaron Lisberg, MD; and Liz Castronovo, NP, discuss hematologic toxicity management during antibody-drug conjugate (ADC) therapy across breast and lung cancer, with particular attention to neutropenia, febrile neutropenia, and growth factor strategies.

This segment focuses on diarrhea management with antibody-drug conjugates (ADCs) across breast and lung cancer, particularly sacituzumab govitecan (SG) and its irinotecan-like toxicity profile due to the SN-38 payload.

Dr. Rugo, NP Stephanie McDonald, and NP Liz Castronovo discussed the distinct gastrointestinal challenges posed by antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan and datopotamab deruxtecan, focusing on "long-delayed nausea" that can persist for days to a week after infusion, a pattern that sets these agents apart from conventional chemotherapy-induced nausea.

The experts conclude their discussion on ocular toxicity by exploring emerging research aimed at addressing the underlying mechanisms of ADC-associated corneal changes.

The experts continue their discussion on ocular toxicity, addressing the practical challenges of distinguishing antibody-drug conjugate (ADC)-related changes from baseline dry eye disease and establishing effective referral pathways.

In this expert discussion, Hope Rugo, MD; Neel Pasricha, MD; and Sarah Sunshine, MD explore ocular adverse events associated with antibody-drug conjugates (ADCs), examining pathophysiology, prevention, and multidisciplinary management.

In this expert discussion, Dr. Hope Rugo, Dr. Aaron Lisberg, Liz Castronovo, NP, and Stephanie McDonald, NP examine mucositis and stomatitis management in antibody-drug conjugate (ADC) therapy for breast and lung cancer.

This discussion brings together Dr. Hope Rugo, Dr. Aaron Lisberg, and Stephanie McDonald, NP discuss interstitial-lung-disease (ILD) risk assessment and monitoring strategies for patients receiving antibody-drug conjugates (ADCs) following radiation therapy.

Panelists discuss proactive ILD risk assessment, vigilant monitoring, and multidisciplinary management to balance safety and efficacy of ADC therapies in breast and lung cancer.

Panelists discuss proactive ILD surveillance, patient education, and early intervention strategies to support safe and effective ADC therapy while minimizing pulmonary risks.

Panelists discuss proactive ILD risk assessment, vigilant monitoring, and multidisciplinary management to balance safety and efficacy of ADC therapies in breast and lung cancer.

Oncology care thrives on teamwork, emphasizing patient education and communication to manage treatment-related ocular toxicities effectively.

Explore the differences in supportive care for antibody-drug conjugates and their impact on ocular health in patients.

Experts discuss the importance of monitoring ocular toxicities in cancer treatment, emphasizing timely interventions and effective communication between oncologists and ophthalmologists.

Experts discuss the alignment of clinical trial data with real-world experiences in managing ocular toxicities in cancer treatments.

Explore the roles of optometrists and ophthalmologists in managing ocular toxicities, ensuring timely patient care and effective treatment strategies.

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.

Explore the latest insights on antibody-drug conjugates in oncology and their associated ocular toxicities, enhancing patient care and treatment outcomes.

Medical oncologists explore the importance of ophthalmology referrals for ocular toxicities, emphasizing collaboration for optimal patient care.

Ophthalmologists discuss the importance of grading dry eye symptoms and the necessity of eye exams before starting certain treatments.

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

Ocular toxicities from cancer treatments present complexities; understanding symptoms and timely ophthalmology involvement is crucial for effective management.

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.